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AbstrAct:
Objective To determine whether the presence of 
hypercapnia on admission in adult patients admitted 
to a university-based hospital in Karachi, Pakistan with 
community-acquired pneumonia (CAP) correlates with an 
increased length of hospital stay and severity compared 
with no hypercapnia on admission.
Study design A prospective observational study.
Settings Tertiary care hospital in Karachi, Pakistan.
Methods Patients who met the inclusion criteria were 
enrolled in the study. The severity of pneumonia was 
assessed by CURB-65 and PSI scores. An arterial blood 
gas analysis was obtained within 24 hours of admission. 
Based on arterial PaCO2 levels, patients were divided 
into three groups: hypocapnic (PaCO2 <35 mm Hg), 
hypercapnic (PaCO2 >45 mm Hg) and normocapnic (PaCO2 
<35–45 mm Hg).
Outcomes The primary outcome was the association of 
hypercapnia on admission with mean length of hospital 
stay. Secondary outcomes were the need for mechanical 
ventilation, ICU admission and in-hospital mortality.
Results A total of 295 patients of mean age 60.20±17.0 
years (157 (53.22%) men) were enrolled over a 1-year 
period. Hypocapnia was found in 181 (61.35%) and 
hypercapnia in 57 (19.32%) patients. Hypercapnic patients 
had a longer hospital stay (mean 9.27±7.57 days), 
increased requirement for non-invasive mechanical 
ventilation (NIMV) on admission (n=45 (78.94%)) and 
longer mean time to clinical stability (4.39±2.0 days) 
compared with the other groups. Overall mortality was 
41 (13.89%), but there was no statistically significant 
difference in mortality (p=0.35) and ICU admission 
(p=0.37) between the three groups. On multivariable 
analysis, increased length of hospital stay was associated 
with NIMV use, ICU admission, hypercapnia and 
normocapnia.
Conclusion Hypercapnia on admission is associated with 
severity of CAP, longer time to clinical stability, increased 
length of hospital stay and need for NIMV. It should be 
considered as an important criterion to label the severity 
of the illness and also a determinant of patients who will 
require a higher level of hospital care. However, further 
validation is required.
IntroductIon
Severe community-acquired pneumonia 
(CAP) is a common infectious condition that 
requires hospitalisation. It is a substantial 
cause of morbidity and mortality worldwide.1 
Limited data are available from Pakistan on 
the incidence of CAP, while studies from 
the USA and Europe have shown an inci-
dence rate of 1600/100 000 population, 
including 250/100 000 requiring hospital-
isation.2 Approximately 10–20% of patients 
with CAP require intensive care unit (ICU) 
admission.3 Mortality may be as high as 58% 
if mechanical ventilation and/or ICU admis-
sion is needed.4
Most patients with CAP improve within 
3 days of hospitalisation with appropriate 
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Research
Strengths and limitations of the study
 ► This is the first study from Pakistan to assess the 
association of hypercapnia with increased length of 
stay (LOS) and severity in adult patients admitted 
with community-acquired pneumonia (CAP) as very 
limited data are available from this part of the world.
 ► Time to clinical stability and LOS, important 
predictors of CAP, were studied in correlation with 
PaCO2 levels.
 ► This is an observational study from a single centre 
with a limited sample size.
 ► It is an observational study which may be influenced 
by season, time of admission and steroid use.
 ► We did not study the underlying cause of death and 
complications which developed during hospital stay 
in these patients.
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antibiotic therapy. Length of hospital stay (LOS) is 
influenced by comorbid conditions, disease severity on 
presentation5 and the time required for clinical stability 
(TCS). The TCS varies from 3 to 7 days; patients with 
more severe CAP on presentation usually require more 
days to achieve clinical stability.6 In a study by Menendez 
et al7 it was found that hypoxaemia, anaemia, hypoalbu-
minaemia and other complications appearing within 
72 hours of admission were associated with prolonged 
hospitalisation. In another study, longer TCS was associ-
ated with poor clinical outcomes and ICU stay.8 However, 
none of these factors correlated with the PaCO2 levels.
Corticosteroids have been analysed in various CAP 
studies and meta-analysis found that the adjunct steroid 
therapy in severe CAP reduces the overall LOS but 
does not alter in-hospital mortality and length of ICU 
stay.9 Prednisolone treatment for 7 days in hospitalised 
patients with CAP was found to have shortened TCS 
without an increase in complications.10 A short steroid 
course decreases the risk of treatment failure and reduces 
radiographic progression of pulmonary infiltrates within 
3–5 days in severe CAP.11
Patients with severe CAP usually present with acute 
respiratory failure, which is the the most common cause 
of death in CAP.12 Various prognostic tools have been 
used to predict the severity of pneumonia. Hypoxaemic 
respiratory failure is a well-known prognostic marker in 
different severity of illness scores.12 13 Relatively newer 
severity scores, such as SCAP14 and SMART-COP,13have 
included low arterial pH as a criterion, but PaCO2 has 
not been used as a predictive variable in any such scores. 
Hypercapnia is considered an indicator of muscle fatigue 
and impending cardiopulmonary arrest. It causes various 
physiological effects on the human body, independent of 
extracellular and intracellular acidosis.15 16
The aim of this study was to determine whether hyper-
capnia (defined as a PaCO2 >45 mm Hg on arterial blood 
gas (ABG) measurement) on admission has any associa-
tion with increased LOS and severity in patients with CAP 
in comparison with those without hypercapnia on admis-
sion.
Methods
setting
This was an observational prospective study conducted 
on patients with a diagnosis of CAP from January to 
December 2014 at Aga Khan University Hospital in 
Karachi, Pakistan. The hospital ethics review committee 
approved the research protocol.
Patients who fulfilled the admission criteria for CAP 
as per British Thoracic Society guidelines were admitted 
to the study.17 Severity was assessed using the Pneu-
monia Severity Index (PSI)18 and CURB-65 score at 
the time of admission. Inclusion criteria were: (1) age 
≥18 years; (2) ABG analysis within 24 hours of admis-
sion; (3) fulfilment of CAP diagnostic criteria based on 
(a) new infiltrates observed on chest X-ray and/or CT 
scan chest, (b) one major criterion (axillary tempera-
ture >37.8°C, cough or expectoration) or at least two 
minor criteria (pleuritic chest pain, dyspnoea, leuco-
cytosis, altered mental status or lung consolidation by 
clinical examination). We excluded patients who had 
a history of hospitalisation in the previous month or 
were transferred from another hospital, patients with 
do not resuscitate or comfort care status and those not 
meeting the criteria for CAP.
The arterial PaCO2 level was assessed by the Cobas b221 
blood gas system (Roche Diagnostics USA) which includes 
pH measurement by electrode ion-selective galvanometer 
and PaCO2, PaO2 measurement by electrode ion-selective 
membrane. ABG analyses were done within 24 hours of 
admission. The patients were divided into three groups 
based on the level of PaCO2 in the arterial blood: (1) 
hypocapnia (PaCO2 level <35 mm Hg); (2) hypercapnia 
(PaCO2 >45 mm Hg); and (3) normocapnia (PaCO2 level 
35–45 mm Hg).
Non-invasive mechanical ventilation (NIMV) was used 
for all those who met one or more eligibility criteria, 
experienced acute respiratory distress at rest, had a respi-
ratory rate of >30 breaths/min and/or excessive use of 
accessory respiratory muscles or paradoxical abdominal 
motion; ABG parameters which included PaO2 <60 mm 
Hg while receiving a high level of fraction of inspired 
oxygen and/or hypercapnia (PaCO2 >45 mm Hg) with 
respiratory acidosis (pH <7.35). The methodology used 
was as described in previous literature.19 NIMV was used 
in the spontaneous mode with the assistance of pulmo-
nary fellows/residents and trained nurses.
In the majority of patients NIMV was started in the 
emergency room but, if the patient was too sick on arrival 
or failed a NIMV trial, then intubation was done imme-
diately. Patients were intubated based on the clinical 
judgement of the physician and/or based on previously 
reported parameters.19 20 NIMV therapy was initiated with 
an inspiratory airway pressure of 10 cm H2O and an expi-
ratory airway pressure of 5 cm H2O. This was optimised 
using continuous pulse oximetry readings, ABG measure-
ments (at 1 hour and periodically thereafter as clinically 
indicated) and patient comfort assessment. The discon-
tinuation of NIMV was based on clinical judgement and 
ABG values.
Patients were excluded from NIMV if they had any of 
the following: (1) severe haemodynamic instability; (2) 
emergency need for cardiopulmonary resuscitation; (3) 
home mechanical ventilation; (4) active vomiting; (5) 
inability to expectorate; (6) neuromuscular weakness; (7) 
contraindications to the use of the mask such as tracheos-
tomy, facial trauma and deformities.
The primary outcome was the association between 
hypercapnia on admission and mean LOS; secondary 
outcomes were need for mechanical ventilation, ICU 
admission and in-hospital mortality. Medical manage-
ment was similar in all three groups with adherence to 
guidelines.17 Oxygen was administered to achieve a level 
of arterial oxygen saturation of >90% by pulse oximetry.
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data source
We used a non-probability consecutive sampling tech-
nique for patient recruitment by assuming LOS is higher 
among hypercapnic patients by 35%,21 with a 95% confi-
dence level, 80% power and odds ratio of 1.93, which 
required a sample of at least 285 patients.
All patients admitted with CAP who met the inclusion 
criteria were included in the study. Informed written 
consent was obtained from the patients or the atten-
dant next of kin. Data were collected on each patient’s 
demographics, age, sex, comorbid conditions, ABG 
values within the first 24 hours of admission, LOS, TCS, 
in-hospital mortality, need for NIMV and ICU admis-
sion/mechanical ventilation on a predesigned proforma. 
Patients were followed till discharge or death, if occurred 
during hospitalisation.
data analysis
All analyses were conducted using the Statistical 
Package for Social Science (SPSS) release 18.0, standard 
version (1989–02). A descriptive analysis of demographic 
features is presented as mean±SD for quantitative 
variables (ie, age, LOS and LOS in the hypocapnia, hyper-
capnia and normocapnia groups) and number (%) for 
qualitative variables (ie, gender, mortality, hypocapnia, 
hypercapnia and normopcania and mortality in hypo-
capnia, hypercapnia and normocapnia groups). A χ2 test 
was used to compare the mortality in the three groups and 
ANOVA was used for mean LOS in the three groups. Due 
to the skewed distribution of LOS, it was categorised for 
the main analysis. LOS was dichotomised into mean <7 
days and >7 days. ORs and their 95% CIs were estimated 
using logistic regression with LOS as the outcome vari-
able. Kaplan–Meier plot analysis was done to assess LOS 
among the three PaCO2 groups. All significant factors 
in the univariate analysis were considered for inclusion 
in the multivariable logistic model. All p values were 
two-sided and p values ≤0.05 were taken as significant.
results
A total of 295 patients were enrolled. The mean 
age was 60.20±17.0 years, 157 (53.22%) were male 
and 138 (46.77%) were female. The majority of the 
patients with CAP were hypocapnic (n=181 (61.35%)) 
while hypercapnia and normocapnia was found in 57 
patients (19.32%) in each group. There was no statis-
tically significant difference in age between the groups 
(p=0.18). Diabetes (n=25 (43.9%), p=0.03) and chronic 
obstructive pulmonary disease (COPD; n=11 (19.3%), 
p<0.001) were more common in the hypercapnic group 
while patients with normocapnia had ischaemic heart 
disease (IHD; n=18 (31.57%), p=0.04). In the hypercapnic 
group, 35 patients (61.40%) had pH <7.35 (p<0.001). 
There was no statistically significant difference in mean 
PaO2 between the three groups (p=0.37).
Hypercapnic patients had a higher CURB-65 score 
(3.14±1.28, p=0.004), PSI score (95.68±29.12, p=0.002), 
renal failure (n=42 (73.68%), p=0.01) and bilateral 
radiographic infiltrates (n=31 (54.4%), p=0.03) on 
presentation compared with the hypocapnic and normo-
capnic groups. The majority of patients with hypercapnia 
received systemic corticosteroids (n=42 (73.7%), 
p<0.001), required NIMV (n=50 (87.71%), p=0.03) and 
had longer TCS (4.39±2.0, p=0.03) compared with hypo-
capnic and normocapnic patients (table 1).
outcome
The mean LOS among patients who survived was 7.4±4.7 
days and was statistically significant in the hypercapnic 
group (8.9±6.8 days, p=0.04). To investigate the correla-
tion between LOS and TCS in steroid users, a subgroup 
analysis was performed. The TCS in steroid users 
remained higher in the hypercapnic group (4.43±2.1 
mean days, p=0.01), but there was no statistically signifi-
cant difference in LOS between steroid users in the three 
groups (p=0.49; table 2)
Among the three groups, ICU admission/endotra-
cheal intubation was required in 56 (18.98%) patients, 
which was not statistically significant (p=0.37). NIMV was 
required in 154 (52.20%) patients, of which 45 (78.94%, 
p=0.03) were in the hypercapnic group. Overall mortality 
was 41 (13.89%) and the difference was not statistically 
significant between the groups (p=0.35). The Kaplan–
Meier curve survival analysis of LOS among the three 
PaCO2 groups is shown in figure 1.
On univariate analysis, hypercapnia, normocapnia on 
admission, in-hospital mortality, IHD, asthma, use of 
systemic steroids, PSI score, ICU admission/intubation 
and NIMV were significantly associated with increased 
LOS. On multivariable analysis, increased LOS in patients 
with CAP was associated with NIMV use, ICU admis-
sion/intubation, normocapnia and hypercapnia and 
was significantly lower in hypocapnic patients (table 3).
dIscussIon
In this observational study of CAP we found that hyper-
capnia on presentation is associated with greater severity 
of CAP, longer TCS and increased need for NIMV 
compared with the other groups. The increased LOS was 
associated with hypercapnia and normocapnia compared 
with hypocapnia. There was no statistically significant 
difference in mortality and intubations/ICU admissions 
between the three groups.
 LOS consists of two components: TCS and the time 
from clinical stability to discharge. This time period 
is important as it translates into the cumulative cost of 
treatment.22 Interestingly, in our study we found that 
hypercapnia leads to longer TCS but, once it is achieved, 
the time to discharge is shorter than for the other groups. 
This longer TCS is probably due to increased severity 
of CAP at the time of presentation. TCS was also longer 
in the subgroup of hypercapnic patients who received 
adjunct steroids. However, there was no statistically 
significant difference in the actual LOS among the three 
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groups of patients who received steroids. We found no 
significant impact of systemic steroids on reducing the 
overall duration of LOS and TCS, as previously noted.9 10
Our results are contrary to those reported in the 
studies by Laserna et al21 and Sin et al,23 which both found 
that hypocapnia and hypercapnia were associated with 
Table 1 Demographic characteristics of patients admitted with community-acquired pneumonia
Normocapnia (PaCO2 
35–45 mm Hg)
Hypocapnia (PaCO2 
<35 mm Hg)
Hypercapnia (PaCO2 
>45 mm Hg) p Value
Total patients
(n=295)
57 (19.32%) 181 (61.35%) 57 (19.32%)
Mean age (years) 61.14±13.85 58.18±18.97 65.77±11.37 0.18
Gender
  Men 18 (31.57%) 108 (59.66%) 31 (54.38%) 0.08
  Women 39 (68.42%) 73 (40.33%) 26 (45.61%)
Season
  January to April 24 (42.1%) 53 (29.3%) 34 (59.6%) 0.001
  May to August 14 (24.6%) 57 (31.5%) 8 (14%)
  September to December 19 (33.3%) 71 (39.2%) 15 (26.3%)
Comorbid 
Diabetes
 
23 (40.35%)
 
50 (27.62%)
 
25 (43.9%)
 
0.03
IHD 18 (31.57%) 33 (18.23%) 14 (24.6%) 0.04
HTN 27 (47.4%) 68 (37.6%) 27 (47.4%) 0.25
COPD 0 4 (2.2%) 11 (19.3%) <0.001
Asthma 3 (5.3%) 25 (13.8%) 10 (17.5%) 0.12
pH
  <7.35 5 (8.7%) 8 (4.4%) 35 (61.40%) <0.001
  >7.35 52 (91.22%) 173 (95.58%) 22 (38.59%)
PaO2 level (mean) 69.13±17.98 71.68±20.16 78.45±35 0.37
PaCO2 level (mean) 37.05±3.65 30.66±9.54 65.36±18.94 <0.001
Serum creatinine
  <1 36 (63.15%) 59 (32.59%) 15 (26.31%) 0.01
  >1 21 (36.84%) 122 (67.40%) 42 (73.68%)
CURB65 (mean±SD) 2.0±1.06 2.37±1.14 3.14±1.28 0.004
PSI (mean±SD) 66.36±32.4 72.39±29.46 95.68±29.12 0.002
Chest X-ray infiltrates
  Unilateral 35 (61.4%) 118 (65.2%) 26 (45.6%) 0.03
  Bilateral 22 (38.6%) 63 (34.8%) 31 (54.4%)
Use of steroids
(systemic)
  Yes 27 (47.4%) 73 (40.3%) 42 (73.7%) <0.001
30 (52.6%) 108 (59.7%) 15 (26.3%)
NIMV therapy
  ER 15 (26.3%) 112 (61.8%) 50 (87.71%) 0.03
  SCU 15 (24.5%) 94 (51.93%) 45 (78.94%)
  ICU 0 0 0
  NIMV failure in ER 0 18 (9.9%) 5 (8.7%)
TCS 
(mean±SD), days
2.76±2.1 3.17±1.99 4.39±2.0 0.03
 COPD, chronic obstructive pulmonary disease; ER, emergency room; HTN, hypertension; IHD, ischaemic heart disease; NIMV, non-invasive 
mechanical failure; PSI, pneumonia severity index ; SCU , special care unit TCS, time to clinical stability.
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increased mortality and ICU admission in patients with 
CAP. Moreover, they did not find any difference in LOS 
among the three groups. Another study by Yassin et al24 
did not find a significant relationship between PaCO2 and 
mortality or ICU admission. However, hypercapnia was 
associated with longer LOS, which was similar to our study. 
We found that hypercapnia correlates well with disease 
severity on presentation as suggested by higher CURB-65 
and PSI scores in hypercapnic patients compared with 
other groups, a finding similar to a previous study.21
Patients with CAP can develop hypercapnia, espe-
cially when receiving high concentration oxygen therapy 
because of the increase in the physiological dead space, as 
observed in COPD.25 26 The severity of the illness itself can 
lead to ventilatory failure in CAP. In our study, 38.59% of 
patients with hypercapnia had a pH of >7.35, suggesting 
chronic hypercapnia. This could be due to unmasking 
of underlying COPD in these patients which was undiag-
nosed until their first presentation to us with CAP.
NIMV is a cost-effective intervention, particularly in 
our region where the majority are unable to bear hospital 
expenses. The requirement for NIMV in patients with 
CAP without any respiratory and cardiac illnesses has 
to be decided cautiously. In our study 5.08% of patients 
had COPD and most were in the hypercapnic group. In 
patients with COPD, Ahmadi et al27 showed that the level 
of alveolar ventilation, as reflected by both hypocapnia 
and hypercapnia, predicts mortality in oxygen-dependent 
COPD patients. However, Aida and colleagues28 found no 
association between PaCO2 and mortality in COPD and 
found hypercapnia to be a favourable factor in oxygen-de-
pendent COPD. Confalonieri et al29 showed in a subset 
analysis that significant benefits of NIMV occurred in 
patients with COPD and hypercapnic respiratory failure, 
as seen in this study.
Hypercapnia causes various effects on the human 
body. A study suggested that, by impairing lung neutro-
phil function, hypercapnia increases mortality in murine 
Pseudomonas pneumonia.15 Hypercapnia inhibits the 
expression of interleukin-6, tumour necrosis factor and 
Table 2 Outcomes of patients admitted with CAP
 
Outcomes
 
Total (n=295)
Normocapnia 
(PaCO2=35–45 mm Hg) 
(n=57)
Hypocapnia 
(PaCO2<35 mm Hg)
(n=181)
Hypercapnia (PaCO2>45 
mm Hg
(n=57) P Value
Mortality 41 (13.89%) 2 (3.5%) 28 (15.46%) 11 (19.29%) 0.35
Intubation 56 (18.98%) 9 (15.78%) 35 (19.3%) 12 (21.05%) 0.37
NIMV use 154 (52.20%) 15 (26.31%) 94 (51.93%) 45 (78.94%) 0.03
Overall
LOS (mean), days
7.3±5.0 9.0±5.2 6.24±3.5 9.27±7.57 0.009
LOS (mean) in 
survivors, days
7.4±4.7 8.7±5.1 6.7±3.5 8.9±6.8 0.04
LOS in steroid 
users who
survived, days
6.3±4.4 6.0±3.5 5.86±2.9 7.57±7.0 0.49
TCS in steroid 
users, days
3.0±1.8 1.89±0.6 2.66±1.5 4.43±2.1 0.001
LOS, length of hospital stay; NIMV, non-invasive mechanical ventilation; TCS, time to clinical stability.
Figure 1 Kaplan–Meier curve showing the length of hospital 
stay among the three PaCO2 groups.
Table 3 Multivariable logistic regression model for length of 
hospital stay in patients with CAP
Odds ratio (95% CI) p Value
IHD 0.39 (0.18 to 0.81) 0.01
NIMV use 3.48 (1.85 to 6.54) <0.001
ICU/intubations 3.96 (1.65 to 9.50) 0.002
Mortality 0.21 (0.08 to 0.56) 0.002
Group
Normal 1.0 <0.001
Hypocapnia 0.13 (0.06 to 0.30) <0.001
Hypercapnia 0.55 (0.22 to 1.39) 0.20
ICU, intensive care unit; IHD, ischaemic heart disease; LOS, length 
of stay >7 days; NIMV, non-invasive mechanical ventilation;.
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phagocytosis in macrophages and causes a defect in resis-
tance to pulmonary infection. This effect was found to be 
independent of extracellular and intracellular acidosis.16 
In another study it was found that hypercapnia inhibits 
autophagy and bacterial killing in human macrophages 
by increasing the expression of B-cell lymphoma 2 (Bcl-2) 
and B-cell lymphoma-extra large (Bcl-xL), which leads 
to immunosuppression and impaired resistance against 
bacteria.30 This inhibition was also not attributable to 
acidosis.
This is the first study from Pakistan that prospectively 
evaluates the association of the PaCO2 level with LOS 
and severity, but this study has some limitations: (1) it 
is a single-centre study with a small sample size; (2) as 
an observational study, there may have been many other 
unobserved confounders that could have affected our 
results (eg, day and time of admission, seasonality, steroid 
use and time to first antibiotic administration); (3) we 
did not study the underlying cause of death in these 
patients; (4) we did not study the complications devel-
oped during the hospital stay; and (5) the decision to use 
adjunct steroid therapy was dependent on the treating 
physician.
conclusIon
This study suggests that hypercapnia on admission is 
associated with severity of CAP, longer TCS, increased 
LOS and need for NIMV in patients admitted with 
CAP. It should be considered as an important criterion 
to label the severity of the illness and also as a deter-
minant of patients who will require a higher level of 
hospital care to prevent the aforementioned outcomes. 
However, further studies are required for validation of 
our results.
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